June Corry

Prof. June Corry


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Sandra NuytsSandra Nuyts
Sandra Nuyts
HBHeleen Bollen
Heleen Bollen
SNSweet Ping Ng
Sweet Ping Ng
JCJune Corry
June Corry
Avraham EisbruchAvraham Eisbruch
Avraham Eisbruch
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
Proton therapy (PT) is a promising development in radiation oncology, with the potential to further improve outcomes for patients with squamous cell carcinoma of the head and neck (HNSCC). By utilizing the finite range of protons, healthy tissue can be spared from beam exit doses that would otherwise be irradiated with photon-based treatments. Current evidence on PT for HNSCC is limited to comparative dosimetric analyses and retrospective single-institution series. As a consequence, the recognized indications for the reimbursement of PT remain scarce in most countries. Nevertheless, approximately 100 PT centers are in operation worldwide, and initial experiences for HNSCC are being reported. This review aims to summarize the results of the early clinical experience with PT for HNSCC and the challenges that are currently faced.

3 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Karthik Nagaraja RaoKarthik Nagaraja Rao
Karthik Nagaraja Rao
Sreeram MpSreeram Mp
Sreeram Mp
Remco De BreeRemco De Bree
Remco De Bree
WMWilliam M. Mendenhall
William M. Mendenhall
Primož StrojanPrimož Strojan
Primož Strojan
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
Objective: To evaluate the impact of postoperative radiotherapy (PORT) on oncological outcomes in node-negative early-stage oral squamous cell carcinoma (OSCC) with perineural invasion (PNI). Methods: A systematic review and meta-analysis was conducted using the PubMed, EMBASE, and Scopus databases for the period from 2000 to 2024. Studies comparing PORT versus observation in pN0 early-stage OSCC with PNI were included. Oncological outcomes assessed included overall survival (OS), disease-free survival (DFS), and local control (LC). A random-effects model was used to calculate log odds ratios, and heterogeneity was assessed using tau2, chi2, and I2 statistics. Results: Seven retrospective studies comprising 522 patients (281 PORT, 241 no-PORT) were included. The 3-year overall survival (OS) was 86.3% in the PORT group compared to 71.1% in the no-PORT group (logOR = −1.03, p = 0.0012), while the 5-year OS was 88.1% versus 77.3% (logOR = −0.97, p = 0.0061). Disease-free survival (DFS) also favored PORT, with 3-year DFS at 86.3% versus 58.1% (logOR = −1.19, p < 0.001) and 5-year DFS at 86.3% versus 55% (logOR = −0.78, p = 0.003). Local control (LC) was higher in the PORT group, with 3-year LC rates of 89% compared to 72.2% in the no-PORT group (logOR = −1.13, p = 0.025). Conclusions: PORT significantly improves OS, DFS, and LC in node-negative early-stage OSCC with PNI as the sole adverse feature.

1 July 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
IAIsuru Amarasena
Isuru Amarasena
AHAlan Herschtal
Alan Herschtal
IDIeta D'COsta
Ieta D'COsta
TFTsien Fua
Tsien Fua
ATAlbert Tiong
Albert Tiong
JCJune Corry
June Corry

1 March 2019 in American Journal of Otolaryngology
Verified
Journal Article
Open access
WMWilliam M. Mendenhall
William M. Mendenhall
Primož StrojanPrimož Strojan
Primož Strojan
JBJonathan J. Beitler
Jonathan J. Beitler
HLHans Langendijk
Hans Langendijk
CSCarlos Suarez
Carlos Suarez
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
A wide variety of tumors, both benign and malignant, occur in the parapharyngeal space. Depending on histology and extent, treatment may include surgery and/or radiotherapy (RT). Herein we discuss the role of RT in the management of some of the more commonly encountered neoplasms, including salivary gland tumors, paragangliomas, schwannomas, and soft-tissue sarcomas.

1 December 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JCJune Corry
June Corry
WNWai Tong Ng
Wai Tong Ng
AMAlisha Moore
Alisha Moore
HCHorace C.W. Choi
Horace C.W. Choi
QLQuynh Le
Quynh Le
ALAnne W.M. Lee
Anne W.M. Lee

1 January 2021 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
PDF file
AKAaron C Kovacs
Aaron C Kovacs
DVDomagoj Vodanovich
Domagoj Vodanovich
EMEmily K Mogridge
Emily K Mogridge
LWLisa Wun
Lisa Wun
JCJune Corry
June Corry
Recurrent respiratory papillomatosis is a human papillomavirus-mediated condition characterised by the development of benign squamous papillomata of the respiratory tract. Malignant transformation of recurrent respiratory papillomatosis, while rare, carries a poor prognosis and there are limited data surrounding treatment options, particularly in inoperable disease. We present the case of a 64-year-old male who developed malignant airway obstruction secondary to primary tracheal squamous cell carcinoma in the setting of a 5-year history of recurrent laryngotracheal papillomatosis, requiring placement of tracheostomy while on veno-venous extracorporeal membranous oxygenation. He was managed with cisplatin-based definitive chemoradiotherapy and had a complete metabolic response on post-treatment positron emission tomography/computed tomography, and remains free of recurrent squamous cell carcinoma at 16 months following treatment. This case supports the use of combined chemoradiotherapy as a potential therapeutic option for patients with primary tracheal squamous cell carcinoma, and emphasises the challenges associated with the long-term management of recurrent respiratory papillomatosis.